Rajeev Menon

2.5k total citations
104 papers, 1.9k citations indexed

About

Rajeev Menon is a scholar working on Hepatology, Infectious Diseases and Genetics. According to data from OpenAlex, Rajeev Menon has authored 104 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Hepatology, 39 papers in Infectious Diseases and 26 papers in Genetics. Recurrent topics in Rajeev Menon's work include Hepatitis C virus research (47 papers), HIV/AIDS drug development and treatment (38 papers) and Chronic Lymphocytic Leukemia Research (24 papers). Rajeev Menon is often cited by papers focused on Hepatitis C virus research (47 papers), HIV/AIDS drug development and treatment (38 papers) and Chronic Lymphocytic Leukemia Research (24 papers). Rajeev Menon collaborates with scholars based in United States, Germany and Egypt. Rajeev Menon's co-authors include Thomas Podsadecki, Ahmed Hamed Salem, Walid M. Awni, Sandeep Dutta, Amit Khatri, Barry Bernstein, Daniel E. Cohen, Akshanth R. Polepally, Prajakta Badri and Suresh Agarwal and has published in prestigious journals such as New England Journal of Medicine, Blood and Clinical Infectious Diseases.

In The Last Decade

Rajeev Menon

100 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rajeev Menon United States	24	908	706	556	307	305	104	1.9k
Daniel Rost Germany	19	313 0.3×	324 0.5×	144 0.3×	302 1.0×	175 0.6×	29	1.7k
Larissa Wenning United States	27	314 0.3×	448 0.6×	1.9k 3.4×	560 1.8×	150 0.5×	71	2.9k
Gabriele Kirchner Germany	25	323 0.4×	339 0.5×	166 0.3×	356 1.2×	62 0.2×	54	2.0k
Jean‐Charles Duclos‐Vallée France	29	1.7k 1.8×	1.5k 2.1×	275 0.5×	220 0.7×	54 0.2×	116	2.5k
Jean‐Didier Grangé France	23	1.2k 1.3×	1.1k 1.6×	86 0.2×	93 0.3×	93 0.3×	52	2.1k
Amit Khatri United States	22	593 0.7×	455 0.6×	285 0.5×	95 0.3×	135 0.4×	47	1.3k
Ken Liu Australia	26	745 0.8×	720 1.0×	76 0.1×	400 1.3×	63 0.2×	122	2.2k
Catherine Stedman New Zealand	26	2.0k 2.2×	1.8k 2.6×	379 0.7×	205 0.7×	31 0.1×	54	2.7k
Akshanth R. Polepally United States	16	412 0.5×	281 0.4×	202 0.4×	91 0.3×	95 0.3×	37	879
Denise Shortino United States	13	290 0.3×	438 0.6×	290 0.5×	180 0.6×	25 0.1×	22	3.1k

Countries citing papers authored by Rajeev Menon

Since Specialization

Citations

This map shows the geographic impact of Rajeev Menon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rajeev Menon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rajeev Menon more than expected).

Fields of papers citing papers by Rajeev Menon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rajeev Menon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rajeev Menon. The network helps show where Rajeev Menon may publish in the future.

Co-authorship network of co-authors of Rajeev Menon

This figure shows the co-authorship network connecting the top 25 collaborators of Rajeev Menon. A scholar is included among the top collaborators of Rajeev Menon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rajeev Menon. Rajeev Menon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patel, Maulik, Jalaja Potluri, Thomas Marbury, et al.. (2025). Pharmacokinetics and Safety of Navitoclax in Hepatic Impairment. Clinical Pharmacokinetics. 64(4). 611–617. 1 indexed citations

Badawi, Mohamed, Sathej Gopalakrishnan, Tammy L. Palenski, et al.. (2024). Dosing of Venetoclax in Pediatric Patients with Relapsed Acute Myeloid Leukemia: Analysis of Developmental Pharmacokinetics and Exposure-Response Relationships. Clinical Therapeutics. 46(10). 759–767.

Badawi, Mohamed, et al.. (2024). Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients. Investigational New Drugs. 42(6). 635–643. 2 indexed citations

Wang, Yamin, Yueli Liu, Rong Deng, et al.. (2024). Venetoclax Clinical Pharmacokinetics After Administration of Crushed, Ground or Whole Tablets. Clinical Therapeutics. 46(10). 752–758. 3 indexed citations

Noorani, Behnam, Rajeev Menon, Xin Chen, et al.. (2023). Venetoclax pharmacokinetics in participants with end‐stage renal disease undergoing haemodialysis. British Journal of Clinical Pharmacology. 90(3). 748–758. 2 indexed citations

Badawi, Mohamed, Sathej Gopalakrishnan, Weize Huang, et al.. (2023). Venetoclax in biomarker‐selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety. Hematological Oncology. 42(1). e3222–e3222. 4 indexed citations

Badawi, Mohamed, Rajeev Menon, Andrew E. Place, et al.. (2023). Venetoclax Penetrates the Blood Brain Barrier: A Pharmacokinetic Analysis in Pediatric Leukemia Patients. Journal of Cancer. 14(7). 1151–1156. 12 indexed citations

Zha, Jiuhong, et al.. (2022). Effects of a ritonavir‐containing regimen on the pharmacokinetics of sirolimus or everolimus in healthy adult subjects. Pharmacology Research & Perspectives. 10(6). e01024–e01024. 2 indexed citations

Badawi, Mohamed, Xin Chen, Patrick Marroum, et al.. (2022). Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet. Clinical Drug Investigation. 42(8). 657–668. 6 indexed citations

10.

Menon, Rajeev, Amit Khatri, Hong Li, et al.. (2018). Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials. European Journal of Clinical Pharmacology. 75(2). 207–216. 6 indexed citations

11.

Mukherjee, Dwaipayan, Jiuhong Zha, Rajeev Menon, & Mohamad Shebley. (2018). Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model. Journal of Pharmacokinetics and Pharmacodynamics. 45(3). 443–456. 21 indexed citations

12.

Gopalakrishnan, Sathej, Brenda Chyla, Sven Mensing, et al.. (2017). Sustained Minimal Residual Disease Negativity Predicted in Chronic Lymphocytic Leukemia Patients Treated with Venetoclax Combination Therapy for 2 Years: an Integrated Mechanistic Analysis of Multiple Phase I and II Studies. Blood. 130. 4318–4318. 2 indexed citations

13.

King, Jennifer R., Jiuhong Zha, Amit Khatri, Sandeep Dutta, & Rajeev Menon. (2017). Clinical Pharmacokinetics of Dasabuvir. Clinical Pharmacokinetics. 56(10). 1115–1124. 15 indexed citations

14.

Polepally, Akshanth R., Sven Mensing, Amit Khatri, et al.. (2016). Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Clinical Pharmacokinetics. 55(9). 1091–1101. 3 indexed citations

15.

Serby, Michael D., Anthony Lee, Xiaomei Zhang, et al.. (2016). Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans. Drug Metabolism and Disposition. 44(8). 1164–1173. 16 indexed citations

16.

Mensing, Sven, Akshanth R. Polepally, Amit Khatri, et al.. (2015). Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 Studies. The AAPS Journal. 18(1). 270–280. 11 indexed citations

17.

Lawitz, Eric, Fred Poordad, Kris V. Kowdley, et al.. (2013). A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. Journal of Hepatology. 59(1). 18–23. 55 indexed citations

18.

Lämmer, Johannes, Dierk Scheinert, Frank Vermassen, et al.. (2011). Pharmacokinetic analysis after implantation of everolimus-eluting self-expanding stents in the peripheral vasculature. Journal of Vascular Surgery. 55(2). 400–405. 6 indexed citations

19.

Menon, Rajeev, et al.. (2007). Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. International Journal of Clinical Pharmacology and Therapeutics. 45(8). 448–454. 35 indexed citations

20.

Menon, Rajeev, et al.. (2007). Effect of the Rate of Niacin Administration on the Plasma and Urine Pharmacokinetics of Niacin and Its Metabolites. The Journal of Clinical Pharmacology. 47(6). 681–688. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact